linjc16/ctgov huggingface dataset:
Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-assisted Laparoscopy and Laparotomy

Study Overview
=================
Brief Summary
-----------------
Objective：To compare the clinical outcomes of endometrial cancer patients who received surgerical treatments: Comparisons of robotic-assisted laparoscopic, laparoscopic and laparotomic methods

Detailed Description
-----------------
We will review the medical records of clinically uterine-confined endometrial cancer women who received robotic-assisted laparoscopic, laparoscopic or laparotomic methods; and compare their outcomes.

Official Title
-----------------
Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-assisted Laparoscopy and Laparotomy

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Procedure: Laparoscopic staging
* Procedure: Robotic staging
* Procedure: Laparotomic staging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: womwn who received endometrial cancer surgical from January 01, 2008 to November 30, 2022 were be reviewed. Exclusion Criteria: Endometrial cancer patients did not undergo surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Laparoscopy<br>Laparoscopic staging group | Procedure: Laparoscopic staging<br>* Laparoscopic staging<br>|
| Robotic<br>Robotic staing group | Procedure: Robotic staging<br>* Robotic staging<br>|
| Laparotomic<br>Laparotomic group | Procedure: Laparotomic staging<br>* Laparotomic staging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | Progression free survival | 5 years | 
| length of hospital stay | length of hospital stay | 2 weeks | 
| surgical time | surgical time | 1 day | 
| Estimate blood loss | Estimate blood loss | 1 day | 
| lymph node number | dissected lymph node number | 1 day |
Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
Highly active hepatitis B virus (HBV) is known to be associated with poor outcomes in patients with hepatocellular carcinoma (HCC). This study aims to investigate the relationship between HBV status and HCC recurrence after liver transplantation. The study retrospectively analyzed HCC patients undergoing liver transplantation in 2 centers between January 2015 and December 2020. We reviewed post-transplant HBV status and its association with outcomes.

Official Title
-----------------
Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma

Conditions
-----------------
Liver Transplant; Complications

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis of postoperative recurrence of liver cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) preoperative diagnosis of HBV-related HCC and (2) pathologically confirmed HCC. Exclusion criteria (1) non-HBV-related HCC; (2) simultaneous presence of other tumors; (3) re-transplantation; (4) presence of portal vein tumor thrombus; and (5) a survival time of less than 90 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| First Affiliated Hospital, Zhejiang University School of Medicine<br> | Diagnostic Test: Diagnosis of postoperative recurrence of liver cancer<br>* HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.<br>|
| Shulan (Hangzhou) Hospital<br> | Diagnostic Test: Diagnosis of postoperative recurrence of liver cancer<br>* HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative recurrence of liver cancer |  | 2015.1.1-2020.12.31 |
Novel Multifocal Soft Contact Lens Study

Study Overview
=================
Brief Summary
-----------------
A single site, open label protocol will be used to evaluate the safety and quality of vision of a novel soft contact lens. Habitual contact lens wearers will be asked to come to the study site for one visit. Ocular health assessments and visual acuity will be completed with both the study lens and without.

Official Title
-----------------
Novel Multifocal Soft Contact Lens Study

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Investigational Contact Lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to give informed consent Any gender Any racial or ethnic origin 18 - 40 years of age Distance visual acuity with best corrected visual acuity of 20/25 with each eye Habitual soft contact lens wearer with myopia Good general health (defined by medication use that has not changed within the last month and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the investigator). Exclusion Criteria: Current or active ocular inflammation or infection as determined by the Investigator. Astigmatism > 0.75 D in either eye History of previous eye surgery Demonstration or history of corneal ectasia or keratoconus. Pregnant or lactating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Distance Visual Acuity<br>Visual acuity will be measured while participant's wear study lenses. | Device: Investigational Contact Lens<br>* A soft contact lens that will be worn only at the study visit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance Visual acuity | The visual acuity of participants while wearing the study lenses. | 1 day (This is a single visit study) |
Research on the Construction of Cord Blood Storage Decision Aid Network Platform Based on Internet +

Study Overview
=================
Brief Summary
-----------------
Cord blood, as an important alternative source of hematopoietic stem cells, can be used to reconstruct bone marrow hematopoietic and immune function, and is an effective means to treat children with blood diseases. However, at present, the collection rate of cord blood is not high in our country, only the mother have the right to decide whether or not. At the same time, domestic studies on cord blood collection are still very limited, for the lack of effective programs and policies, which can not provide help to improve the collection level of cord blood. Therefore, in order to improve the rate of umbilical cord blood collection, it is particularly necessary to build tools to help pregnant women decide whether to retain cord blood. This topic will investigate and analyze the cognition and retention intention of pregnant women for umbilical cord blood collection. At the same time, the related process of pregnant women for umbilical cord blood retention will be deeply explored. Based on the results of quantitative and qualitative investigation, Internet technology will be used to build a network platform for pregnant women for umbilical cord blood storage decision AIDS, and the effectiveness of this tool will be evaluated. To provide theoretical basis for clinical medical workers and umbilical cord blood bank staff to establish the decision plan of cord blood storage.

Official Title
-----------------
Research on the Construction of Cord Blood Storage Decision Aid Network Platform Based on Internet +

Conditions
-----------------
Pregnant Women

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old; Pregnant women whose gestational age ≥12 weeks and registered in our hospital; With a certain level of education, can complete the questionnaire independently; Informed consent to participate in the study Exclusion Criteria: There are patients with mental illness; Participated in other clinical studies in the past three months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Construct the network platform of cord blood storage decision aid tool | Construct the network platform of cord blood storage decision aid tool based on Internet + and apply it to clinical practice to provide support and help for pregnant women in cord blood storage decision, avoid decision regret, and improve pregnant women's willingness and satisfaction in cord blood storage. | 2024.07.10 |
Results at More Than 10 Years of Meniscal Sutures Without Avivement

Study Overview
=================
Brief Summary
-----------------
Currently, suturing the lesion is recommended rather than the classic meniscectomy, which leads to early and subsequent gonarthrosis. The most commonly practiced technique is arthroscopic suturing after avivement the area to be sutured to promote healing. But the real benefit of this enhancement has never been documented. The complexity of the surgical procedure makes the acceptability of this indication low by orthopedic surgeons at present (10% sutures compared to 90% meniscectomies). The aim of the study is to evaluate the 10-year survival rate of meniscal sutures without avivement.

Official Title
-----------------
Results at More Than 10 Years of Meniscal Sutures Without Avivement

Conditions
-----------------
Knee Arthroscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (≥18 years old) Gender indifferent Patient operated on at the HUS between January 1, 2011 and June 30, 2013 Medial or lateral meniscal lesion of the knee treated by arthroscopic suture without sharpening with or without reconstruction of the anterior cruciate ligament. Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes. Exclusion Criteria: Subject having expressed his opposition to the reuse of his data for scientific research purposes. Subject under judicial protection Subject under guardianship or curatorship Meniscal lesion not sutured or sutured with sharpening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 10-year survival rate of meniscal sutures without avivement |  | 10 years after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
knee arthroscopy, Meniscal suture, Meniscal lesion, Meniscectomy, Arthroscopic suturing
Clinical Study of QSOX1 as a Biomarker for Colon Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.

Detailed Description
-----------------
The project mainly selects the tumor group represented by colon cancer and the corresponding healthy people as the control group, with about 100 cases in each of the two groups. Mainly collect blood and tumor tissue samples of patients, detect the expression of QSOX1 in the above samples, and explore the role in the diagnosis and prognosis evaluation of colon cancer.

Official Title
-----------------
Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis of colon cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colon cancer was confirmed by colonoscopic pathology. No local or systemic treatment was performed before operation. Complete clinical data. Exclusion Criteria: Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp. Other tumors other than colon cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumor group<br>First diagnosis of colon cancer. | Diagnostic Test: Diagnosis of colon cancer<br>* Clinical diagnosis results<br>|
| Control group<br>Healthy people. | Diagnostic Test: Diagnosis of colon cancer<br>* Clinical diagnosis results<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of RNA for early rapid diagnosis of colon cancer. | RT-PCR was used to detect the RNA levels of QSOX1 in the tumor and control groups. | 6 months | 
| Detection of protein for early rapid diagnosis of colon cancer. | Western blotting was used to detect the protein levels of QSOX1 in the tumor and control groups. | 6 months |
Stellate Ganglion Block to Treat Long COVID 19 Case Series

Study Overview
=================
Brief Summary
-----------------
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.

Detailed Description
-----------------
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.

Official Title
-----------------
Stellate Ganglion Block to Treat Long COVID-19 Syndrome, A 41 Patient Retrospective Cohort Study

Conditions
-----------------
Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia, Dysgeusia, Brain Fog, Muscle Pain, Shortness of Breath, Dizziness, Fatigue Post Viral, Cough, Menstrual Cycle Abnormal, Pain

Intervention / Treatment
-----------------
* Procedure: Stellate Ganglion Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado. - Exclusion Criteria: Stellate Ganglion Block Contraindications -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SGB Patients for Long COVID 19<br>Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics. | Procedure: Stellate Ganglion Block<br>* Ultrasound guided block of the Stellate Ganglion with local anesthetics.<br>* Other names: SGB;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom Response | Evaluation of the symptoms response to the Stellate Ganglion Block | 3 months |
Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Study Overview
=================
Brief Summary
-----------------
This is a Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of IMM0306 in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL).

Official Title
-----------------
Phase I/II Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Conditions
-----------------
CD20-positive B-cell Non-Hodgkin's Lymphoma

Intervention / Treatment
-----------------
* Drug: IMM0306


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (B-NHL) that has been diagnosed, including but not limited to diffuse large B-cell lymphoma (DLBCL) Follicular lymphoma (FL), mucosal lymphoma (MALT-L), small lymphocytic lymphoma (SLL) / chronic lymphocytic leukemia (CLL). At least one measurable or assessable tumor lesion. Adequate organ and hematologic function. Eastern Co-operative Oncology Group (ECOG) score 0 to 2. All adverse events from prior treatment must be CTCAE v5.0 grade <= 1 Exclusion Criteria: Active central nervous system (CNS) lymphoma. Systemic steroid therapy (dose equivalent to > 10 mg prednisone / day). History of severe allergic reactions to macromolecular protein preparations/monoclonal antibodies and any test drug components (CTCAE v5.0 grade >=3). Have evidence of severe uncontrollable active infection. Subjects have deep vein embolism or pulmonary embolism within 6 months before screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IMM0306 Monotherapy<br>Phase I dose escalation part, participants with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (B-NHL) will be enrolled to receive IMM0306. The dose of IMM0306 will depend on when you join this study. About 1-6 participants will be enrolled at each dose level. Phase II dose expansion part, participants will receive IMM0306 at the recommended dose that was found in dose escalation part. | Drug: IMM0306<br>* IMM0306 is an bi-specific antibody<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose-limiting toxicity |  | Evaluated for DLTs during the first 28-day cycle | 
| Complete response rate |  | up to 52 weeks |
Life-dependent Home Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
In Denmark, life-dependent home-mechanical ventilation (HMV) is given under the surveillance of a specifically trained respiratory patient caregiver (tPCG). The HMV can be invasive through a tracheostomy or non-invasive via a mask. The purpose of this study is to uncover experiences and challenges associated with having a trained respiratory patient care giver (tPCG) to surveil home-mechanical ventilation (HMV) from the perspective of the patients and their families and to gather information about the expirence of working in a home as a tPCG

Official Title
-----------------
Experiences and Challenges in Life-dependent Home Mechanical Ventilation - a Part of the Air For Life Project

Conditions
-----------------
Ventilator Lung

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient Age > 18 years Has trained patient care givers to surveil the respiratory treatment and working on the responsibility of the Respiratory Center East Parent Age > 18 years Has a child less than 18 years old with tPCG, working on the responsibility of the Respiratory Center East, to surveil the home-mechanical ventilation Other relative: Age > 18 years Involved in the treatment or support of a relative with tPCG, working on the responsibility of the Respiratory Center East, to surveil the home-mechanical ventilation Trained patient caregivers (tPCG) Age > 18 years Employed by an external agency or by the patient (BPA) to surveil home-mechanical ventilation Certified as tPCG working on the responsibility of the Respiratory Center East Exclusion Criteria: No informed consent to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br> | |
| Relatives<br> | |
| Trained respiratory patient caregiver<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severe respiratory insufficiency questionnaire | The patients will be asked to fullfill the questionnaire | Assessed within the last 7 days |